CAR mechanics: Driving T cells into the MUC of cancer

Cancer Research

Volumn 69, Issue 11, 2009, Pages 4559-4562

  Maher, John ^a   Wilkie, Scott ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHIMERIC ANTIGEN RECEPTOR; FC RECEPTOR; HOX PROTEIN; HYBRID PROTEIN; IMMUNOMODULATING AGENT; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; MUCIN 1; RECOMBINANT MUCIN 1 IMMUNOGLOBULIN G FUSION PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; CARCINOGENESIS; EPITOPE MAPPING; GENETIC ENGINEERING; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; MOLECULAR CLONING; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN TARGETING; REACTION OPTIMIZATION; REVIEW; STEREOSPECIFICITY; T LYMPHOCYTE ACTIVATION; VARIABLE NUMBER OF TANDEM REPEAT;

ANIMALS; CHEMOTAXIS, LEUKOCYTE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOTHERAPY; MODELS, BIOLOGICAL; MUCIN-1; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 66349117960     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0564     Document Type: Review

References (20)

1. Hattrup CL, Gendler SJ. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol 2008;70:431-457 PubMed doi:10.1146/annurev physiol.70.113006.100659.
2. Gaemers IC, Vos HL, Volders HH, van der Valk SW, Hilkens J. A stat-responsive element in the promoter of the episialin/MUC1 gene is involved in its overexpression in carcinoma cells. J Biol Chem 2001;276:6191-6199 PubMed doi:10.1074/jbc M009449200. (Pubitemid 37373474)
3. Hilkens J, Buijs F, Hilgers J, et al. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer 1984;34:197-206. PubMed doi:10.1002/ijc. 2910340210. (Pubitemid 14053141)
4. Burchell JM, Mungul A, Taylor-Papadimitriou J. O-linked glycosylation in the mammary gland: changes that occur during malignancy. J Mammary Gland Biol Neoplasia 2001; 6:355-64. PubMed doi:10.1023/A:1011331809881. (Pubitemid 39600493)
5. Girling A, Bartkova J, Burchell J, Gendler S, Gillett C, Taylor-Papadimitriou J. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer 1989;43:1072-1076 PubMed doi:10.1002/ijc.2910430620. (Pubitemid 19158040)
6. Burchell J, Gendler S, Taylor-Papadimitriou J, et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 1987;47:5476-5482 PubMed. (Pubitemid 17152966)
7. Wilkie S, Picco G, Foster J, et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol 2008;180:4901-4909 PubMed.
8. Ragupathi G, Liu NX, Musselli C, Powell S, Lloyd K, Livingston PO. Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J Immunol 2005;174:5706-5712 PubMed. (Pubitemid 40593213)
9. Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat Biotechnol 2002;20:70-75 PubMed doi:10.1038/nbt0102-70. (Pubitemid 34044918)
10. Engelmann K, Kinlough CL, Müller S, et al. Transmembrane and secreted MUC1 probes show trafficking-dependent changes in O-glycan core profiles. Glycobiology 2005;15:1111-1124 PubMed doi:10.1093/glycob/cwi099. (Pubitemid 41662638)
11. Løset GA, Roux KH, Zhu P, Michaelsen TE, Sandlie I. Differential segmental flexibility and reach dictate the antigen binding mode of chimeric IgD and IgM: implications for the function of the B cell receptor. J Immunol 2004;172:2925-2934 PubMed. (Pubitemid 38263679)
12. Pulè MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005;12:933-941 PubMed doi:10.1016/j ymthe.2005.04.016. (Pubitemid 41614489)
13. Vera J, Savoldo B, Vigouroux S, et al. T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 2006;108:3890-7. PubMed doi:10.1182/blood-2006-04-017061. (Pubitemid 44864573)
14. van de Wiel-van Kemenade E, Ligtenberg MJ, de Boer AJ, et al. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol 1993;151:767-776 PubMed. (Pubitemid 23215742)
15. Guest RD, Hawkins RE, Kirillova N, et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother 2005;28:203-211 PubMed doi:10.1097/01.cji.0000161397.96582.59. (Pubitemid 40593985)
16. Hombach AA, Schildgen V, Heuser C, Finnern R, Gilham DE, Abken H. T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells. J Immunol 2007;178:4650-4657 PubMed. (Pubitemid 46492418)
17. James SE, Greenberg PD, Jensen MC, et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol 2008;180:7028-7038 PubMed.
18. Davis SJ, van der Merwe PA. The kinetic-segregation model: TCR triggering and beyond. Nat Immunol 2006;7:803-809 PubMed doi:10.1038/ni1369. (Pubitemid 44084086)
19. Sulchek TA, Friddle RW, Langry K, et al. Dynamic force spectroscopy of parallel individual Mucin1-antibody bonds. Proc Natl Acad Sci US A 2005;102:16638-16643 PubMed doi:10.1073/pnas.0505208102. (Pubitemid 41688829)
20. Doi M, Yokoyama A, Kondo K, et al. Anti-tumor effect of the anti-KL-6/MUC1 monoclonal antibody through exposure of surface molecules by MUC1 capping. Cancer Sci 2006;97:420-429 PubMed doi:10.1111/j.1349-7006.2006.00183. x.